11.2 Anticoagulation, Reversal & Hemostatic Agents

11.2 Anticoagulation, Reversal & Hemostatic Agents

Cardiothoracic, major vascular, and trauma surgical procedures require precise, real-time control of the patient's coagulation cascade. Anesthesia technologists play a vital frontline role in setting up point-of-care coagulation monitors (such as Activated Clotting Time machines), reconstituting hemostatic concentrates, and preparing reversal agents. Understanding the pharmacology of unfractionated heparin, the mechanics of heparin resistance, protamine neutralization stoichiometry, antifibrinolytics, and transfusion-related calcium homeostasis is critical for patient safety and successful certification.

---

Unfractionated Heparin (UFH): Mechanism & Dosing

Unfractionated Heparin (UFH) is a heterogeneous, naturally occurring, polyanionic glycosaminoglycan extracted commercially from porcine intestinal mucosa or bovine lung tissue. It has a molecular weight ranging from 3,000 to 30,000 Daltons (mean ~15,000 Da).

Mechanism of Action: The Antithrombin III Catalyst

Heparin itself has zero intrinsic enzymatic or anticoagulant activity. Instead, it functions as an allosteric catalytic accelerator of Antithrombin III (AT-III), an endogenous serine protease inhibitor synthesized by the liver:

UNFRACTIONATED HEPARIN (Pentasaccharide Sequence)
                      |
                      v  (Binds with High Affinity)
             ANTITHROMBIN III (AT-III)
                      |
                      v  (Induces 3D Conformational Change)
   AT-III INHIBITORY RATE ACCELERATED > 1,000-FOLD
                      |
         +------------+------------+
         |                         |
         v                         v
FACTOR IIa (Thrombin)      FACTOR Xa (Stuart-Prower)
   INACTIVATED               INACTIVATED
(Also inactivates Factors IXa, XIa, and XIIa)

1. Pentasaccharide Core: Approximately one-third of circulating heparin chains contain a unique, high-affinity pentasaccharide sequence. This sequence binds specifically to lysine sites on AT-III.
2. Conformational Change: Heparin binding induces an irreversible 3D conformational change in AT-III, projecting its reactive center loop into an active state that accelerates its rate of binding to and neutralizing Factor IIa (Thrombin) and Factor Xa by over 1,000-fold.
3. Chain Length Dynamics: To inhibit thrombin (Factor IIa), heparin must be long enough (> 18 saccharide units, MW > 5,400 Da) to form a tertiary bridging complex enveloping both AT-III and thrombin simultaneously. In contrast, to inhibit Factor Xa, only the pentasaccharide binding to AT-III is required; bridging to the enzyme is unnecessary.

Perioperative Indications & Dosing Regimens

• Cardiopulmonary Bypass (CPB): Requires full systemic anticoagulation to prevent massive, lethal thrombus formation when blood contacts the foreign plastic surfaces, oxygenator fibers, and tubing of the heart-lung machine. The standard loading dose is 300 to 400 units/kg IV, administered through a dedicated, reliable central venous line, aspirated, and flushed completely (or injected directly into the right atrium by the surgeon).
• Vascular Surgery: Procedures requiring cross-clamping of major arteries (e.g., carotid endarterectomy, abdominal aortic aneurysm repair, peripheral vascular bypass) require moderate systemic anticoagulation to prevent arterial stasis thrombosis. The standard dose is 50 to 100 units/kg IV, administered approximately 3 to 5 minutes prior to arterial cross-clamp placement.
• Elimination Half-Life: The half-life of unfractionated heparin is dose-dependent, averaging 60 to 90 minutes at typical clinical doses (up to 120-150 minutes at high CPB doses). Clearance occurs via rapid saturable reticuloendothelial uptake followed by slower renal elimination.

---

Activated Clotting Time (ACT) Monitoring

Standard laboratory coagulation assays (such as aPTT) are unusable during surgical procedures because their turnaround time is too long (30-60 minutes) and their clotting endpoints cap at 100 to 150 seconds. The Activated Clotting Time (ACT) is a rapid, point-of-care whole-blood test developed by Hattersley that evaluates real-time high-dose heparin anticoagulation.

Technical Operation & Activator Types

A sample of fresh whole blood (typically 0.5 to 2.0 mL) is drawn directly from the patient's arterial line (after discarding fluid flush) and injected into an ACT test cartridge or vial containing an activator of the intrinsic coagulation pathway and a magnetic or mechanical sensor:

• Celite Cartridges: Contain diatomaceous earth (purified siliceous phytoplankton skeletons). Celite strongly activates Factor XII. Clinical Note: Aprotinin (a serine protease inhibitor) artificially prolongs celite ACT; kaolin must be used if aprotinin is present.
• Kaolin Cartridges: Contain hydrated aluminum silicate particles. Kaolin is unperturbed by aprotinin and provides consistent activation.

The machine warms the blood to 37°C and rotates or oscillates the vial. When thrombin cleaves fibrinogen into a solid fibrin clot, the clot catches a magnetic stir-bar or mechanical flag, halting its movement and recording the elapsed time in seconds.

Clinical Thresholds & Protocols

Technical Caveat: The ACT is a functional biological assay that can be prolonged by non-heparin variables, including severe hypothermia (< 32°C), severe hemodilution (low hematocrit on bypass), severe thrombocytopenia (< 50,000/mcL), platelet receptor inhibitors, and hypofibrinogenemia.

---

Heparin Resistance: Pathophysiology & Management

Heparin resistance is defined clinically as the failure to achieve the target therapeutic ACT (> 400 to 480 seconds for CPB) despite the administration of standard or supratherapeutic loading doses of unfractionated heparin (> 400 to 600 units/kg).

                    PATIENT RECEIVES HEPARIN 300-400 U/kg
                                      |
                                      v
                         ACT CHECKED AT 5-10 MINUTES
                                      |
        +-----------------------------+-----------------------------+
        |                                                           |
        v (ACT > 480 seconds)                                       v (ACT < 400 seconds)
ADEQUATE ANTICOAGULATION                                      HEPARIN RESISTANCE
Proceed with Cannulation & CPB                                      |
                                                                    v
                                                  ADMINISTER ADDITIONAL HEPARIN
                                                  (100-200 units/kg IV bolus)
                                                                    |
                                                                    v
                                                      REPEAT ACT AT 5-10 MINUTES
                                                                    |
                                      +-----------------------------+-----------------------------+
                                      |                                                           |
                                      v (ACT > 480 seconds)                                       v (ACT Still < 400 seconds)
                               PROCEED WITH CPB                                         CONFIRMED AT-III DEFICIENCY
                                                                                                  |
                                                                    +-----------------------------+-----------------------------+
                                                                    |                                                           |
                                                                    v                                                           v
                                                      FIRST-LINE TREATMENT:                                      SECOND-LINE TREATMENT:
                                                      ANTITHROMBIN III CONCENTRATE                               FRESH FROZEN PLASMA (FFP)
                                                      (Thrombate III: 500-1000 units IV)                         (2 to 4 units IV)

Etiology of Heparin Resistance

1. Antithrombin III Deficiency (Leading Cause): Because heparin relies entirely on AT-III to inhibit coagulation factors, a deficiency in circulating AT-III paralyzes heparin's anticoagulant capability.
   • Acquired AT-III Deficiency: The most common clinical scenario. Preoperative unfractionated or low-molecular-weight heparin therapy lasting > 48 to 72 hours accelerates AT-III clearance, depleting circulating AT-III reserves by 30% to 50%. Other acquired causes include septic shock, acute deep vein thrombosis/pulmonary embolism, disseminated intravascular coagulation (DIC), nephrotic syndrome (urinary loss of AT-III), and hepatic cirrhosis.
   • Congenital AT-III Deficiency: Rare autosomal dominant disorder resulting in baseline AT-III levels < 50% of normal.
2. Non-AT-III Causes: High circulating levels of Factor VIII, severe thrombocytosis (platelets release Platelet Factor 4 [PF4], a basic protein that binds and neutralizes heparin), and ongoing active systemic inflammation.

Clinical Management Protocol

When a patient fails to reach an ACT > 400 to 480 seconds after an initial 300 to 400 units/kg loading dose:

• Step 1: Administer an additional bolus of heparin (100 to 200 units/kg).
• Step 2: If repeat ACT remains refractory (< 400 seconds), do NOT continue administering blind heparin boluses. Exogenous AT-III must be replenished immediately:
  • First-Line Pharmacotherapy: Antithrombin III Concentrate (e.g., Thrombate III, recombinant or purified human plasma-derived). Dosed at 500 to 1,000 units IV (or weight-based formula: [Target AT-III % (100) - Baseline AT-III %] x weight [kg] / 1.4). Reconstituted in sterile water and infused over 10 minutes; rapidly restores heparin responsiveness without volume overload or pathogen transmission risk.
  • Second-Line Pharmacotherapy: Fresh Frozen Plasma (FFP). Administer 2 to 4 units IV. Each milliliter of FFP contains approximately 1 unit of endogenous functional AT-III. However, FFP carries the drawbacks of volume expansion, thawing delays, and transfusion-related acute lung injury (TRALI) risk.

---

Protamine Sulfate: Neutralization & Adverse Reactions

Protamine sulfate is a strongly basic, low-molecular-weight (4,000 to 5,000 Da) polycationic peptide purified from the sperm or mature testes of the salmon (Oncorhynchus keta or chum salmon). Its primary amino acid sequence consists of > 65% basic, positively charged arginine residues.

Stoichiometric Neutralization Kinetics

Heparin is the most negatively charged polyanionic biological molecule in the human body, rich in sulfate and carboxylate groups. When basic protamine is injected into the bloodstream, it binds acidic heparin in an instantaneous, stoichiometric acid-base reaction:

Heparin(-) + Protamine(+) ===> [Heparin-Protamine Ionic Salt Complex]

The resulting stable, neutral ionic salt complex possesses zero anticoagulant activity and is rapidly engulfed and cleared by the reticuloendothelial system.

Dosing Calculations & Protamine Rebound

• Standard Neutralization Ratio: 1.0 mg of protamine sulfate neutralizes approximately 100 units of active circulating unfractionated heparin.
• Calculating the Reversal Dose: The protamine dose should never be calculated based strictly on the original heparin loading dose if significant time has elapsed, because heparin has an elimination half-life of 60 to 90 minutes. For example, if a patient received 30,000 units of heparin 2 hours earlier and the half-life is 60 to 90 minutes, roughly 7,500 to 12,000 units remain active, which corresponds to about 75 to 120 mg of protamine rather than the full 300 mg. In practice, ACT or heparin-concentration monitoring guides the final dose. Over-administration must be avoided.
• Intrinsic Anticoagulant Hazard of Excess Protamine: When administered in significant stoichiometric excess (or in the complete absence of heparin), unbound protamine functions as an anticoagulant. Free protamine binds platelets, inhibits platelet aggregation, and exerts an antithrombin effect by inhibiting Factor V and thrombin activation, paradoxically aggravating post-CPB coagulopathic microvascular bleeding.
• Heparin Rebound: Can occur in cardiac surgical patients 2 to 6 hours postoperatively. Heparin that had been sequestered in extravascular depots (fat, skeletal muscle, lymphatics, and endothelium) leaches back into the intravascular space, or protamine is enzymatically cleared faster than heparin. Manifests as sudden postoperative chest tube bleeding, elevated aPTT, and prolonged ACT. Treated with small supplemental intravenous doses of protamine (25 to 50 mg IV).

Protamine Adverse Reaction Phenotypes

Protamine is associated with three distinct, well-defined clinical adverse reaction phenotypes that every anesthesia technologist must recognize:

+-----------------------------------------------------------------------------------------+
|                         PROTAMINE ADVERSE REACTION PHENOTYPES                           |
+-----------------------------------------------------------------------------------------+
| TYPE I: SYSTEMIC HYPOTENSION                                                            |
| - Cause: Rapid intravenous injection (< 5-10 minutes).                                  |
| - Mechanism: Direct peripheral vascular smooth muscle relaxation and non-immunologic    |
|   histamine release from tissue mast cells and basophils.                               |
| - Presentation: Transient drop in systemic vascular resistance (SVR), hypotension,      |
|   warm cutaneous flushing.                                                              |
| - Prevention / Management: Administer slowly over 10 to 15 minutes; fluid loading;     |
|   phenylephrine / norepinephrine.                                                       |
+-----------------------------------------------------------------------------------------+
| TYPE II: ANAPHYLACTIC / ANAPHYLACTOID HYPERSENSITIVITY                                  |
| - Cause: Immunologic sensitization (IgE-mediated) or complement activation.             |
| - High-Risk Groups:                                                                     |
|   1. Chronic NPH Insulin Users: Neutral Protamine Hagedorn contains protamine to slow  |
|      absorption; chronic exposure triggers anti-protamine IgE/IgG antibodies.           |
|   2. Prior Vasectomy: Disruption of the blood-testis barrier exposes sperm antigens;    |
|      anti-sperm antibodies cross-react with salmon sperm-derived protamine.             |
|   3. Documented Fish / Seafood Allergy: Cross-reactivity with salmon proteins.          |
|   4. Prior Protamine Exposure: Previous cardiac catheterization or cardiac surgery.     |
| - Presentation: Severe bronchospasm, facial angioedema, urticaria, massive capillary   |
|   leak, profound circulatory collapse, and shock.                                       |
| - Management: Stop infusion; 100% O2; Epinephrine (10-100 mcg IV bolus); H1/H2         |
|   antihistamines; Hydrocortisone (100-200 mg); aggressive volume resuscitation.         |
+-----------------------------------------------------------------------------------------+
| TYPE III: CATASTROPHIC PULMONARY HYPERTENSION                                           |
| - Cause: Idiosyncratic reaction mediated by Heparin-Protamine macromolecular complexes. |
| - Mechanism: Heparin-protamine complexes activate the classical complement cascade,     |
|   generating anaphylatoxin C5a, which stimulates pulmonary macrophages to release       |
|   massive quantities of Thromboxane A2 and Endothelin-1.                                |
| - Presentation: Catastrophic, acute surge in Pulmonary Artery Pressure (PAP), acute    |
|   Right Ventricular (RV) dilation and failure, severe left ventricular underfilling,    |
|   precipitous drop in systemic arterial blood pressure, and pink frothy pulmonary edema.|
| - Management: Immediately STOP protamine; administer Inhaled Pulmonary Vasodilators    |
|   (Inhaled Prostacyclin / Epoprostenol or Inhaled Nitric Oxide [iNO]); inotropic        |
|   support (Milrinone, Epinephrine); vasopressin for systemic SVR; emergent reinstitution|
|   of Cardiopulmonary Bypass (re-heparinization and cannulation) if arrest occurs.       |
+-----------------------------------------------------------------------------------------+

---

Antifibrinolytic Pharmacology: TXA & Amicar

During major surgery and cardiopulmonary bypass, mechanical shear stress, foreign surfaces, and tissue trauma stimulate the release of endogenous tissue plasminogen activator (tPA). tPA cleaves inactive circulating plasminogen into the active fibrinolytic enzyme plasmin. Plasmin digests stable fibrin meshes into soluble fibrin degradation products (FDPs / D-dimer), dissolving hemostatic clots and precipitating diffuse microvascular surgical hemorrhage.

Mechanism of Action: Lysine Analogs

Tranexamic Acid (TXA) and Epsilon-Aminocaproic Acid (EACA / Amicar) are synthetic derivatives of the basic amino acid lysine:

     PLASMINOGEN MOLECULE                                  FIBRIN CLOT MESH
[Lysine-Binding Sites (LBS)] <==============X==============> [Lysine Residues on Fibrin]
              ^                                             (Binding Blocked)
              |
      TXA / AMICAR (Binds LBS)

1. Reversible Competitive Blockade: TXA and EACA bind with high affinity to the lysine-binding sites (LBS) on the kringle domains of plasminogen and plasmin.
2. Prevention of Fibrin Binding: By occupying these sites, antifibrinolytics prevent plasminogen from binding to the lysine residues on fibrin polymers. Consequently, plasminogen cannot be cleaved into active plasmin on the clot surface, and existing plasmin cannot digest the fibrin clot, preserving structural clot integrity.

Tranexamic Acid vs. Epsilon-Aminocaproic Acid

• Potency: Tranexamic acid is 6 to 10 times more potent than epsilon-aminocaproic acid on a milligram-for-milligram basis and exhibits stronger binding to plasminogen.
• Clinical Dosing:
  • Cardiac Surgery (TXA): 10 to 30 mg/kg IV loading dose administered over 20 to 30 minutes, followed by a continuous infusion of 1 to 5 mg/kg/hr throughout the case (or a standardized 1 to 2 g total dose).
  • Orthopedic Arthroplasty (TXA): 1 g IV pre-incision followed by 1 g IV at wound closure (or 1 to 3 g administered topically into the joint capsule).
  • Trauma (CRASH-2 Protocol): 1 g IV infused over 10 minutes administered within 3 hours of injury, followed by 1 g IV infused over the subsequent 8 hours. (In CRASH-2, starting after 3 hours was associated with more deaths from bleeding.)
  • Amicar (EACA): Requires large gram-level doses: 5 g IV loading dose over 30 minutes, followed by a continuous infusion of 1.0 to 1.25 g/hr.
• Adverse Neurotoxicity (TXA Seizures): High doses of tranexamic acid cross the blood-brain barrier and act as competitive antagonists of GABA-A and glycine inhibitory neurotransmitter receptors in the cerebral cortex. This reduction in neuronal inhibition can trigger postoperative grand mal seizures, observed particularly in open-chamber cardiac surgery, elderly patients, and patients with unadjusted doses in chronic renal failure.

---

Calcium Salts & Citrate Chelation in Massive Transfusion

Ionized calcium (Ca2+, Factor IV) is an indispensable, rate-limiting cofactor throughout the coagulation cascade. It anchors coagulation factor complexes to negatively charged platelet phospholipid surfaces (via gamma-carboxyglutamic acid residues), driving the tenase (IXa-VIIIa-Ca2+) and prothrombinase (Xa-Va-Ca2+) catalytic cascades that generate thrombin.

Citrate Toxicity & Hypocalcemia

Stored blood products (Packed Red Blood Cells [PRBCs], Fresh Frozen Plasma [FFP], and Platelets) are preserved with anticoagulant solutions containing citrate (e.g., Citrate-Phosphate-Dextrose-Adenine / CPDA-1). Citrate works in the blood bag by binding and chelating ionized calcium, preventing in vitro clot formation.

Under normal circumstances, transfused citrate is rapidly cleared and metabolized by the liver via the citric acid (Krebs) cycle (half-life ~5 minutes). However, during Massive Transfusion Protocols (MTP)—defined as transfusion of > 1 unit of PRBCs every 5 to 10 minutes or > 10 units in 24 hours—the rate of citrate delivery overwhelms hepatic metabolic capacity, especially in the presence of hypothermia, shock, or hepatic hypoperfusion:

1. Severe Acute Hypocalcemia: Circulating citrate strips ionized calcium from the blood, plunging serum ionized calcium below critical levels (normal: 1.15 to 1.30 mmol/L; toxicity manifests at < 0.90 to 1.0 mmol/L).
2. Cardiovascular Collapse: Loss of extracellular calcium impairs excitation-contraction coupling in the myocardium, causing severe arterial hypotension, decreased cardiac output, elevated ventricular filling pressures, and prolonged QTc intervals on the ECG predisposing to Torsades de pointes.
3. Transfusion Coagulopathy: Hypocalcemia halts thrombin generation, exacerbating acute trauma coagulopathy and worsening microvascular bleeding.

Calcium Chloride vs. Calcium Gluconate

Anesthesia technologists frequently prepare calcium salts during major resuscitation. Understanding the chemical and clinical distinctions between 10% Calcium Chloride and 10% Calcium Gluconate is critical:

Rule of Thumb: One gram of Calcium Chloride delivers approximately three times the elemental calcium of one gram of Calcium Gluconate, so roughly 3 g of gluconate replaces 1 g of chloride. Calcium chloride is favored when rapid, large repletion is needed during massive transfusion or arrest, and it should be infused through a central line whenever feasible because of its extravasation risk.